Mainly because individuals that have the APOE e4 gene variant seem to possess a better hazard of serious complications, the FDA recommends being tested for the gene variant before starting treatment with lecanemab or donanemab. Tests for dementia provide a single bit of the puzzle. They must not substitute for https://allanv864tdm3.estate-blog.com/profile